Abstract
The new BASKET design of clinical trials represents a smart solution to overcome modest and temporary efficacy of a single anti-EGFR or anti-VEGF drug in advanced unresectable colorectal cancers.
The validity and low cost of targeted Next Generation sequencing (tNGS) to explore known gene panels with matched approved drugs for other cancer types has recently provided promising progression-free and overall survival rates for early-phase recent clinical trials. Advances and challenges in combination of drugs targeting specific genetic mutations and supportive immunotherapy are discussed.

(Citation: Gastric & Breast Cancer 2020; 15(1): 31-36)

Back

PDF Version